Terlipressin Administration in Septic Shock Refractory to Catecholamines

Phase 2

• Conditions: Septic Shock
• Interventions: Drug: terlipressin

• Registration Number: NCT00793559
• Lead Sponsor: Assaf-Harofeh Medical Center

Brief Summary

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

Detailed Description

Not available

Study Timeline

• Status Verified: 2008-11
• Study Start: 2008-11
• Study First Submitted: 2008-11-18
• Study First Submitted QC: 2008-11-18
• Last Update Submitted: 2008-11-18
• Study First Posted: 2008-11-19
• Last Update Posted: 2008-11-19
• Primary Completion: 2009-07
• Study Completion: 2009-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• septic shock patients receiving above 0.5 mcg/kg NA

Exclusion Criteria

• allergy to terlipressin, CHF, IHD, pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
terlipressin bolus	terlipressin	1 mg of terlipressin received one time only
terlipressin drip	terlipressin	-

Primary Outcome Measures

Name	Time	Method
CI, SVR,HR,BP, noradrenalin administration,renal function	6 mo

Trial Locations

Locations (1)

Asaf Harofeh MC; 🇮🇱 Zrifin, Israel